期刊文献+

用Bicine-NaOH缓冲液制备的尿酸酶复合纳米脂质体中尿酸酶的生化特性 被引量:3

Preparation and property of uricase in uricase-catalase Bicine-NaOH nanoliposomes
原文传递
导出
摘要 目的研究Bicine-Na OH缓冲液制备的尿酸酶(UCA)-过氧化氢酶纳米脂质体(UCNL)中UCA的生化特性及初步稳定性。方法使用Bicine-Na OH缓冲液并采用逆向蒸发法制备UCNL,考察UCNL的形态结构、粒径分布、Zeta电位、包封率及UCNL中UCA的最适温度、最适p H、米氏常数和热稳定性、贮存稳定性、酸碱稳定性、抗胰蛋白酶水解能力和抗部分金属离子和有机化合物的能力。结果 UCNL呈类圆形,包封率为56.87%±3.81%,粒径为759.30±28.12 nm,Zeta电位为-8.49±3.18 m V。UCNL中UCA和游离UCA的最适温度均为40℃,最适p H分别为8.0、8.5,Km值分别13.40、13.87μmol·L-1;UCNL中UCA的各种稳定性均比游离UCA好。结论 UCNL中UCA的催化活性和稳定性较游离酶明显增加。 OBJECTIVE To investigate tile biochemical characteristics and stabilities of uricase(UCA) loaded in uricase - catalase nannliposomes(UCNL) which were produced by Bicine - NaOH buffer solution. METHODS UCNL were prepared using rcverse - phase evaporation,in which Bicine - NaOH buffer was used. Its morphology, size distribution,Zeta potential and encapsulation efficiency were investigated. Optimum temperature, optimum pH, michaelis - menten constand, thermal stabilities, storage stabilities, pH stabili- ties,stabilities to proteolytic digestion and stabilities to several metal ions and organic compounds of UCA in UCNL and free UCA were primarily examined. RESULTS The shape of UCNL was similar round. The average entrapment efficiency of UCNL was 56.87% ± 3.81%. Tbe particle size of UCNL was 759.30 ± 28.12 nm, and the Zeta potential was - 8.49 ± 3. 18 inV. Optimum temperature of UCA in UCNL and free UCA was 40 ℃ , and optimum pH value of UCA in UCNL and free UCA were 8.0 and 8.5, respectively. Mictmelis - menten constand of UCA in UCNL and free UCA were 13.40 μmol·L^-1 and 13.87 μmol·L^-1. Various stabilities of UCA in UCNL were better than free UCA. CONCLUSION The activity and stabilities of UCA in UCNL are better than free UCA.
出处 《华西药学杂志》 CAS CSCD 2015年第5期543-546,共4页 West China Journal of Pharmaceutical Sciences
基金 国家自然科学基金资助项目(批准号:30973645)
关键词 尿酸酶 过氧化氢酶 纳米脂质体 生化特性 稳定性 包封率 逆向蒸发法 Uricase Catalase Nanoliposomes Biochemical characteristics Stabilities Encapsulation efficiency Revere - phase evaporation
  • 相关文献

参考文献6

  • 1Krishnan E,Kwoh CK,Schumacher HR,ef al. Hyperuricemia andincidence of hypertension among men without metabolic syndrome[J]. Hypertension,2007 ,49(2) :298 -303.
  • 2Freitas DS,Spencer PJ, Vassao RC ,et al. Biochemical and biop-harmaceutical properties of PEGylated uricase [ J ]. Int J Pharm,2010,387(1 -2) :215 -222.
  • 3Halliwell B, Clement MV, Long LH. Hydrogen peroxide in thehuman body[ J]. Febs Lett,2000,486( 1) :10 - 13.
  • 4陈焱,黄健花,蔡春明,王兴国.过氧化氢酶固体脂质纳米粒的制备[J].食品与生物技术学报,2011,30(4):489-494. 被引量:4
  • 5Tan QY,Wang N,Yang H,ef al. Preparation and characterizationof lipid vesicles containing uricase[ J] . Drug Deliv,2010,17( 1):28 -37.
  • 6王娜,赵春景,黄开顺,滕永真,张景勍.产朊假丝酵母尿酸酶脂质纳米粒的制备及其药效学特性分析[J].中国生物制品学杂志,2013,26(8):1147-1150. 被引量:15

二级参考文献20

  • 1刘冰,梁婵娟.生物过氧化氢酶研究进展[J].中国农学通报,2005,21(5):223-224. 被引量:130
  • 2孟尧,辛渝,谭晓晶,许晓燕,余彩霞,杨波,孟延发.朊圆酵母尿酸酶的基本特性研究[J].四川大学学报(自然科学版),2006,43(2):414-419. 被引量:6
  • 3M. Garcia-Fuentes. Design of lipid nanopartieles for the oral delivery of hydrophilie macromolecules[J]. Colloids and Sur- faces B: Biointerfaces,2002 (27) : 159-168.
  • 4B Gander, E Wehrl, R Alder. Quality improvement of spray-dried, protein-loaded D,L-PLA micro-spheres by appropri- ate polymer solvent selection[J]. Mi-eroencapsulation, 1995 (12): 83 - 97.
  • 5XIE Shu-yu, WANG Si-liang, ZHOU Wen-zhong,et al. Effect of PLGA as a polymeric emulsifier on preparation of hy- drophilic protein-loaded solid lipid nanoparticles[J]. Colloids and Surfaces B: Biointerfaees, 67 (2008) 199- 204.
  • 6Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: Influence of the formulation and processing parameters[J]. European Journal of Pharmaceutical Sciences, 2006,27 ( 2 - 3) : 143 - 149.
  • 7LI Ya-ping, PEI Yuan-ying, GAO Xiu-jian,et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, prepara- tion and biodistribution in rats[J ]. Journal of Controlled Release, 2001,71 ( 2 ): 203 - 211.
  • 8Lucienne J. The targeted delivery of cancer drugs across the blood-brain barrier:chemical modifications of drugs or drug- nanoparticales[J]. Drug Discovery Today, 2008,13 ( 23 - 24 ) : 1099 - 1106.
  • 9Gulyaev AE, Gelperina SE,Skidan IN et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles[J]. Pharmaceutical Research, 1999,16(10) :1564- 1569.
  • 10Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase / xanthine-dehydrogenase inhibitor for the management of hype- ruricemia in adults with gout [J]. Clin Ther, 2009, 31 (11): 2503-2518.

共引文献15

同被引文献21

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部